Medscape24d
Rationale and Early Clinical Data on IL-17 Blockade in Psoriasis
Five subjects withdrew from the study because of adverse events, including two patients who had erythrodermic psoriasis in the early dosing arm. A total of 20 subjects experienced grade 1 or 2 ...
Longview News-Journal27d
Head-to-Head Preclinical Studies of SFA-002 as a Novel Psoriasis Treatment Presented at the 2025 American Academy of Dermatology Annual Meeting
Mice dosed with SFA-002 displayed reduction in psoriasis disease severity and greater ... About SFA Therapeutics SFA Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing ...
pharmaphorum2y
Dermavant claims its first approval as FDA clears psoriasis drug
Roivant group company Dermavant has made the transition to a commercial-stage company after ... J&J wants to turn the screw in the psoriasis market with a new head-to-head trial pitting oral ...
Yahoo Finance26d
Head-to-Head Preclinical Studies of SFA-002 as a Novel Psoriasis Treatment Presented at the 2025 American Academy of Dermatology Annual Meeting
Mice dosed with SFA-002 displayed reduction in psoriasis disease severity and greater reduction in skin thickening compared to etanercept and apremilast in the in vivo model SFA-002 reduced key ...